By Billy Candra 
Researchers from a collaborative effort involving the Francis Crick Institute, the UCL Cancer Institute, and UCLH have unveiled significant advancements in lung cancer prognostics, demonstrating that a novel test dubbed ORACLE can predict lung cancer survival at the point of diagnosis with greater accuracy than existing clinical risk factors. This breakthrough, detailed in the prestigious journal Nature Cancer, holds profound implications for individuals diagnosed with stage 1 lung cancer, offering the potential to guide more informed treatment decisions, thereby mitigating the risk of disease recurrence or metastasis and significantly improving patient outcomes.
ORACLE: A New Frontier in Lung Cancer Prognosis
Lung cancer stands as the leading cause of cancer-related mortality globally, responsible for an estimated 1.8 million deaths each year. In the United Kingdom, it accounts for approximately 35,000 deaths annually, highlighting an urgent need for more effective diagnostic and prognostic tools. While advancements in screening and treatment have led to improved survival rates over recent decades, particularly for early-stage disease, a significant challenge persists: accurately identifying which early-stage patients face a higher risk of recurrence and could benefit from more aggressive or tailored therapies.
Current clinical standards for assessing lung cancer prognosis primarily rely on factors such as tumour stage (based on the TNM system – Tumour, Node, Metastasis), tumour size, and histological characteristics. While these factors provide a general framework, they often lack the granularity to predict individual patient trajectories with high precision, especially in early-stage disease. For instance, approximately a quarter of patients diagnosed with stage 1 lung cancer, who typically undergo surgery without adjuvant chemotherapy, experience a relapse. This suggests that a substantial subset of these individuals might have benefited from additional monitoring or systemic treatment, underscoring a critical unmet need for better risk stratification.
The ORACLE test was initially developed in 2019 precisely to address this deficit in biological markers for lung cancer. Its core innovation lies in its ability to overcome a fundamental challenge in cancer biology: tumour heterogeneity. Tumours are not uniform masses; they are complex ecosystems composed of diverse cell populations with varying genetic profiles. Traditional biopsies, which sample less than 1% of a tumour, often fail to capture this internal variability, leading to an incomplete understanding of the cancer’s true biological nature and its potential for aggression. ORACLE circumvents this limitation by analyzing gene expression levels across various regions within a tumour, providing a comprehensive molecular snapshot that reflects the tumour’s overall genetic landscape and its inherent instability.
TRACERx Study Validates Predictive Power
The latest research, conducted as part of the Cancer Research UK-funded TRACERx (TRAcking Cancer Evolution through therapy) study, rigorously tested ORACLE’s efficacy in a cohort of 158 individuals diagnosed with lung cancer. TRACERx is a pioneering, long-running study designed to understand how lung cancer evolves and adapts over time and in response to treatment, providing invaluable insights into tumour biology. The findings unequivocally demonstrated that ORACLE possessed superior predictive capabilities for patient survival compared to currently used clinical standards, including tumour stage. This validation marks a significant milestone, moving ORACLE closer to potential clinical application.
The study specifically highlighted ORACLE’s profound impact on stage 1 lung cancer patients. For this group, existing clinical standards frequently fall short in identifying those at higher risk of adverse outcomes. ORACLE, however, proved capable of predicting which stage 1 patients had a lower chance of survival, indicating a strong likelihood that these individuals would benefit from adjuvant chemotherapy in addition to surgical intervention. This capability is transformative, as it enables clinicians to differentiate between patients who may be adequately treated with surgery alone and those who require a more aggressive, multi-modal approach from the outset, potentially averting devastating recurrences.
Beyond predicting survival, the research also uncovered crucial insights into the biological underpinnings of tumour behaviour. High ORACLE risk scores were found to be intrinsically linked to specific regions within a tumour that exhibited a greater propensity for metastatic spread. This correlation provides valuable information not only about prognosis but also about the inherent metastatic potential of the cancer, offering another layer of insight for treatment planning.
Targeting Metastasis and Optimizing Chemotherapy
A particularly exciting aspect of the study was its exploration of ORACLE’s ability to predict response to specific therapeutic agents. By analyzing 359 current and potential lung cancer drugs, the researchers discovered that a high ORACLE risk score was a strong predictor of a better response to certain types of chemotherapy, most notably platinum-based drugs such as cisplatin and carboplatin. This finding is critical for personalizing treatment, allowing oncologists to select the most effective chemotherapy regimen for individual patients based on their tumour’s molecular profile.
The mechanistic explanation behind this observed correlation lies in the tumour’s genomic instability. Tumour regions characterized by high ORACLE scores are associated with elevated levels of ‘chromosomal instability’ – a state where a cell’s chromosomes exhibit frequent structural and numerical changes. This chromosomal instability makes cancer cells particularly vulnerable to DNA-damaging agents like platinum drugs, which exert their cytotoxic effects by forming adducts with DNA, leading to DNA strand breaks and ultimately cell death. The same research group had previously identified changes in a key gene called FAT1 as a driver of chromosomal instability, a genetic variation that ORACLE also specifically assesses. This intricate interplay between gene expression, chromosomal instability, and drug sensitivity forms the scientific bedrock of ORACLE’s predictive power.
The Global Burden of Lung Cancer and the Need for Innovation
Lung cancer continues to pose an immense global health challenge. Despite significant research efforts, its prognosis remains poorer than many other common cancers, largely due to late diagnosis and the aggressive nature of the disease. The five-year survival rate for lung cancer in the UK, for instance, is around 17%, significantly lower than for breast (85%) or prostate (87%) cancer. While early detection through screening programmes is improving outcomes, the ability to accurately stratify risk at the point of diagnosis, particularly for early-stage disease, is paramount. This is where technologies like ORACLE promise to revolutionize patient care.
The journey of a patient diagnosed with lung cancer is often fraught with uncertainty. The traditional "one-size-fits-all" approach to treatment is increasingly being replaced by the paradigm of personalized medicine, where therapeutic strategies are tailored to the unique biological characteristics of each patient’s tumour. ORACLE embodies this shift, moving beyond crude anatomical staging to a more sophisticated molecular understanding of the disease.
Expert Commentary and Collaborative Efforts
The research team emphasized the transformative potential of ORACLE. Dhruva Biswas, a co-first author from the Crick, UCL Cancer Institute, and Yale School of Medicine, articulated the significance of these findings: "ORACLE can now predict survival rates in patients diagnosed at the earliest stage. If validated in larger cohorts of patients with lung cancer, doctors could one day use ORACLE to help make informed treatment decisions, bringing lessons from cancer evolution into the clinic."
Yun-Hsin Liu, another co-first author from the UCL Cancer Institute, highlighted the comprehensive nature of the test: "We’ve also shown that it can predict who would benefit from certain types of chemotherapy drugs or if someone’s cancer is likely to spread, giving a holistic measure of how a patient’s cancer might progress and respond."
Professor Charles Swanton, Deputy Clinical Director and Head of the Cancer Evolution and Genome Instability Laboratory at the Crick, Chief Investigator for TRACERx, and co-senior author, underscored the critical need for such tools: "Lung cancer is the leading cause of cancer-related death throughout the world, so it’s clear we need better markers to accurately classify tumours and predict who is at high risk." He also confirmed ongoing efforts to accelerate clinical implementation: "We’re now working with the Translation team at the Crick and industry partners to progress ORACLE into a test which could hopefully be used in the clinic as soon as possible."
Paul Mercer, Head of Industry Partnerships in the Crick Translation team, echoed this sentiment, emphasizing the translation of complex biological understanding into tangible patient benefits: "This is an important step forward, translating our understanding of the infinite complexities of lung cancer mutation into a diagnostic tool, prioritising patients for the most effective therapies."
Dani Edmunds, Science Engagement Manager at Cancer Research UK, lauded the research as a testament to the commitment to tackling hard-to-treat cancers. "New tests to predict lung cancer’s behaviour could help doctors tailor treatment strategies to each person’s condition, giving the best chance of a successful outcome," she remarked, acknowledging that while larger trials are needed, these initial results represent a crucial step towards more personalized lung cancer treatment.
From Bench to Bedside: The Path to Clinical Implementation
The immediate next steps for the researchers involve conducting larger-scale validation studies. These studies will compare outcomes in patients with high ORACLE scores who receive standard care against those who receive more intensive surveillance or adjuvant chemotherapy. The ultimate goal is to definitively determine if the integration of ORACLE into clinical practice leads to improved survival rates, even for patients diagnosed at the earliest stages of the disease.
The transition from a promising research tool to a routinely used clinical diagnostic test is a complex process, involving rigorous validation, regulatory approvals, and the development of scalable, cost-effective testing platforms. The collaboration between academic institutions, funding bodies like Cancer Research UK, and industry partners is crucial in navigating this pathway efficiently. The involvement of the National Institute for Health and Care Research UCLH Biomedical Research Centre further highlights the multidisciplinary and translational nature of this endeavour.
A Paradigm Shift Towards Precision Oncology
The development and validation of ORACLE represent a significant leap forward in the field of precision oncology. By providing a more accurate and nuanced understanding of individual tumour biology, ORACLE empowers clinicians to move beyond generalized treatment protocols towards truly personalized strategies. This not only promises to improve survival and quality of life for lung cancer patients but also offers the potential for more efficient healthcare resource allocation by targeting expensive and often toxic therapies only to those most likely to benefit.
As the scientific community continues to unravel the complexities of cancer evolution, tests like ORACLE will become increasingly vital. They stand as a testament to the power of integrating advanced genomic and molecular analyses into clinical decision-making, offering a beacon of hope for patients facing one of the most challenging cancers to treat. The journey from discovery to widespread clinical use is ongoing, but the foundation laid by this research offers a compelling vision for a future where lung cancer treatment is not just reactive, but precisely predictive and profoundly effective.
